Should investors worry about INBS's earnings trend?

**Investors should not necessarily worry about INBS's earnings trend**, as the company is demonstrating positive signs of growth and strategic resilience:

1. **Growth in Gross Profit**: Intelligent Bio Solutions Inc. has reported a 32.6% surge in gross profit, driven by higher-margin cartridge sales and market expansion efforts. This indicates a strong financial performance and effective business strategies.
2. **Revenue Growth and Market Expansion**: Despite relatively low revenue generation, the company has shown a year-on-year revenue growth of 23%, supported by a growing customer base and international expansion efforts. The anticipated entry into the U.S. drug screening market in 2025 through FDA submission and strategic partnerships suggests a promising growth trajectory.
3. **Strategic Focus on Higher-Margin Sales**: The company's focus on higher-margin cartridge sales is driving profitability and long-term growth. This strategic shift has led to an anticipated increase in gross profit margin to 38.5%, reflecting enhanced profitability.
4. **Financial Stability and Expansion Plans**: INBS's financial performance supports long-term financial stability and expansion, with sustained growth in gross profit and gross profit margin. The company's operational highlights and business updates indicate a proactive approach to market penetration and innovation.

While it is important for investors to monitor the company's progress in achieving its growth targets and addressing potential challenges, the current trends and strategic initiatives suggest that INBS is moving in a positive direction. Investors should maintain a cautious optimism, considering the potential for future growth and the company's strategic positioning in the market.